Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26639689 | 1.00 | HTR6 (0.46) | HTR6HTR2AHTR2CHTR2B | |
| SCHEMBL26646007 | 1.00 | HTR6 (0.46) | HTR6HTR2AHTR2CHTR2B | |
| SCHEMBL31377432 | 0.91 | HTR6 (0.39) | HTR6HTR2AHTR2CHTR2B | |
| SCHEMBL25629069 | 0.89 | HTR6 (0.43) | HTR6 | |
| SCHEMBL26642932 | 0.89 | HTR6 (0.43) | HTR6 | |
| SCHEMBL14446996 | 0.84 | HTR2A (0.39) | HTR2AHTR2CHTR2B | |
| SCHEMBL7448411 | 0.83 | HTR2A (0.39) | HTR2AHTR2CHTR2B | |
| SCHEMBL11737985 | 0.83 | HTR6 (0.43) | HTR6 | |
| SCHEMBL11647423 | 0.82 | HTR6 (0.45) | HTR6 | |
| SCHEMBL13761639 | 0.81 | HTR2B (0.41) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353827-A1 | INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC (CA) | 2025-11-20 | — | — | US | disclosed |
| EP-4511360-A1 | INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Mindset Pharma Inc. (CA) | 2025-02-26 | — | — | EP | disclosed |
| CN-119522212-A | Indoline derivatives as serotonergic agents for the treatment of related disorders | 思维模式制药公司 | 2025-02-25 | — | — | CN | disclosed |
| WO-2023201421-A1 | INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023201421-A1 | INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2023-10-26 | — | — | WO | disclosed |
| US-6187805-B1 | TREATING CONDITION FOR WHICH SELECTIVE AGONISM OR ANTAGONISM OF 5-HT-6 RECEPTORS IS INDICATED BY ADMINISTERING COMPOUNDS SUCH AS N,N-DIMETHYL 2-(1-(BENZENESULPHONYL)-5-METHOXY-1H-INDOL-3-YL)ETHYLAMINE | MERCK SHARP & DOHME LTD. (GB) | 2001-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353827-A1 | INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | TPH1, TPH2, HTR5A | HTR6 11/4885HTR2A 5/4885HTR2C 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.